세계의 위암 치료 시장(2023-2030년)

Overview

Global Stomach Cancer Treatment Market reached US$ 4.7 billion in 2022 and is expected to reach US$ 10.3 billion by 2030 growing with a CAGR of 8.7% during the forecast period 2023-2030.

Stomach cancer is a disease in which malignant (cancer) cells are formed in the stomach lining. Stomach cancer usually begins in the mucus-producing cells that line the stomach. Symptoms of stomach cancer include indigestion and stomach discomfort or pain. Most people typically do not show signs in the earlier stages due to which diagnosis becomes difficult. Because of this, it often goes undiagnosed until after it spreads to other body parts and cause metastasis.

Gastric cancer is the third leading cause of death throughout the world. According to the National Cancer Institute, 1.8% of the deaths caused by cancer are due to stomach cancer. According to the American Cancer Society estimate in 2022, stomach cancer accounts for about 1.5% of all new cancers in the U.S. annually.

Furthermore, the rising incidence of gastric cancer, the adoption of a sedentary lifestyle and irregular food habits, and rising research and development in the oncology sector are a few factors that are expected to drive the market in the forthcoming period.

Dynamics

Increasing Product Launches

Gastric cancer is currently the fifth most frequently diagnosed cancer and the fourth leading cancer-related cause of death worldwide. Over 90-95% of cases are classified as adenocarcinoma. The American Cancer Society's 2022 estimates include 26,380 new cases and 11,090 deaths from gastric cancer.

For instance, in February 2023, Enhertu launched gastric cancer tertiary treatment in South Korea. The first and only HER2 target ADC, which improves treatment for advanced and metastatic gastric cancer.

Additionally, in April 2023, HUTCHMED (China) Limited was granted a New Drug Application ("NDA") for fruquintinib along with paclitaxel for the treatment of second-line progressive gastric or gastroesophageal junction adenocarcinoma in China was accepted for consideration by the China National Medical Products Administration ("NMPA").

Increasing Drug Pipeline

Various biotech and pharmaceutical companies are developing various drugs which are in the pipeline. Companies like CNBG-Virogin Biotech, Minneamrita Therapeutics LLC, etc. These drugs are tested for safety and efficacy in treating gastric cancer. Combination drugs are given to the patients to observe the effectiveness of the therapy.

Zhejiang Cancer Hospital along with CSPC Ouyi Pharmaceutical Co., Ltd. are conducting a phase 3 clinical trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage 3 gastric cancer as adjuvant setting. The estimated completion date is October 31, 2024.

Complications Related to Radiotherapy and Chemotherapy

Chemotherapy and radiotherapy are the leading treatments for stomach cancer. Chemotherapy may also lead to implications such as sunlight sensitivity and increasing sunburn risk. Chemotherapy can cause individuals to become temporarily lactose intolerant. Both chemotherapy and radiation therapy for stomach cancer can cause diarrhea, nausea, and vomiting. Radiation toward the pelvis and some chemotherapy drugs lead to urinary tract infections (UTIs). Apart from treating stomach cancer, it can decrease estrogen levels, causing symptoms like vaginal dryness and conditions like primary ovarian insufficiency, testosterone levels, and sperm count.

Segment Analysis

The global stomach cancer treatment market is segmented based on cancer type, treatment type, end-user, and region.

Chemotherapy can target cancer cells that have spread beyond the stomach or shrink the tumor before surgery and alleviate symptoms in advanced cases of gastric cancer. The use of chemotherapy in gastric cancer is rapidly evolving, and the optimal treatment strategy may vary depending on the tumor's molecular characteristics, the stage of cancer, and other individual factors.

Due to the increased use of chemotherapy treatment for stomach cancer, there is an increase in chemotherapeutic products in the market. For instance, in April 2022, BDR Pharmaceuticals launched Furmecil, a generic oral drug for treating advanced gastric cancer.

Furthermore, in June 2023, Merck & Co.'s Keytruda, in a new phase 3 trial, Keytruda plus chemotherapy, significantly extended patients' lives over chemo alone in newly diagnosed HER2-negative gastric or gastroesophageal junction cancers that are advanced or metastatic. The Keytruda combination cut the risk of death by 22%.

Geographical Analysis

North America accounts for the largest market share for stomach cancer treatment. The American Cancer Society's estimates for stomach cancer (also known as gastric cancer) in the United States for 2023 are about 26,500 new cases of stomach cancer (15,930 in men and 10,570 in women).

In addition to that, lifestyle factors such as improper diet and smoking cause gastric cancer. Diets high in salt, smoked or pickled foods, and low in fruits and vegetables have been linked to an increase in the risk of gastric cancer. Similarly, smoking is a most common risk factor for gastric cancer and the prevalence of smoking in many countries in North America remains high. All these factors are anticipated to boost the growth of the North American gastric cancer market during the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has also had a massive impact on secondary care. Hospitals and health centers reduced their functioning capacity to maintain social distancing measures by government guidelines, which consequently delayed cancer diagnosis. A March 2021 report noted a 60% decrease in new oncology clinical trials during the pandemic, fueling concerns regarding slowing the development of new cancer therapies. A major UK-based cancer research charity, Cancer Research UK, halted recruitment in 95% of their clinical trials to protect cancer patients including stomach cancer, and cope with the redeployment of clinical research staff to support frontline COVID-19-facing healthcare services.

By Type

• Adenocarcinoma
• Gastrointestinal stromal tumors (GIST)
• Carcinoid tumors
• Lymphoma
• Others

By Treatment Type

• Surgery
  • Endoscopic mucosal resection
  • Gastrectomy

• Subtotal

• Total
  • Endoluminal stent placement
  • Endoluminal laser therapy
  • Gastrojejunostomy

• Radiation therapy

• Chemotherapy
  • Capecitabine
  • Cisplatin
  • Docetaxel
  • Oxaliplatin
  • Paclitaxel
  • Hyperthermic intraperitoneal chemotherapy (HIPEC)
  • Others

• Targeted therapy
  • Ramucirumab
  • Regorafenib
  • Trastuzumab

• Immunotherapy
  • Nivolumab
  • Pembrolizumab

• Others

By Distribution Channel

• Hospitals and Clinics
• Cancer Centers
• Cancer Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb signed an outsourcing agreement with Prime Research Institute for Medical RWD, Inc. Kyoto, Japan, an industry-sponsored, large-scale, multi-institutional clinical research in patients with gastric cancer treated with Opdivo in combination with chemotherapy.
• In February 2023, AstraZeneca signed a global exclusive license agreement deal with KYM Biosciences, a joint venture established by affiliates of Keymed Biosciences and Lepu Biopharma. The deal is centered around CMG901, an antibody-drug conjugate (ADC) currently being evaluated as a potential treatment for gastric cancer.
• In November 2022, Organon, a global women's health company, declared the availability and distribution of ONTRUZANT, a biosimilar of Herceptin, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer.

Competitive Landscape

The major global players in the stomach cancer treatment market include: Merck & Co., Inc, Bristol-Myers Squibb, Accord Healthcare, Sanofi S.A, Bayer Pharma AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Celltrion, Inc., Genentech, Inc., and Winthrop US among others.

Why Purchase the Report?

• To visualize the global stomach cancer treatment market segmentation based on cancer type, treatment type, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of stomach cancer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global stomach cancer treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Cancer Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Product Launches
    • 4.1.1.2. Increasing Drug Pipeline
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Related to Radiotherapy and Chemotherapy
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Cancer Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Adenocarcinoma
• 7.3. Gastrointestinal stromal tumors (GIST)
• 7.4. Carcinoid tumors
• 7.5. Lymphoma
• 7.6. Others

8. By Treatment Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.1.2. Market Attractiveness Index, By Treatment Type
• 8.2. Surgery
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Endoscopic mucosal resection
  • 8.2.4. Gastrectomy
  • 8.2.5. Endoluminal stent placement
  • 8.2.6. Endoluminal laser therapy
  • 8.2.7. Gastrojejunostomy
• 8.3. Radiation therapy
• 8.4. Chemotherapy
  • 8.4.1. Capecitabine
  • 8.4.2. Cisplatin
  • 8.4.3. Docetaxel
  • 8.4.4. Oxaliplatin
  • 8.4.5. Paclitaxel
  • 8.4.6. Others
• 8.5. Targeted therapy
  • 8.5.1. Ramucirumab
  • 8.5.2. Regorafenib
  • 8.5.3. Trastuzumab
  • 8.5.4. Others
• 8.6. Immunotherapy
  • 8.6.1. Nivolumab
  • 8.6.2. Pembrolizumab
  • 8.6.3. Hyperthermic intraperitoneal chemotherapy (HIPEC)
  • 8.6.4. Others
• 8.7. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital and Clinics
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Cancer Care Centers
• 9.4. Cancer Research Institutes
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Merck & Co.
  • 12.1.1. Company Overview
  • 12.1.2. Type Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Bristol-Myers Squibb
• 12.3. Accord Healthcare
• 12.4. Sanofi S.A.
• 12.5. Bayer Pharma AG
• 12.6. Eli Lilly and Company
• 12.7. Teva Pharmaceuticals Industries, Ltd.
• 12.8. Celltrion, Inc.
• 12.9. Genentech, Inc.
• 12.10. Winthrop US

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us